← All indications
von Hippel-Lindau Disease
An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.
Drugs by status
Approved for this indication (1)
Phase 2 trials (15)
Phase 1 trials (4)
Other trials (2)
Organizations
Organization Involved with Phase 2 Indications (14)
- Genentech
- Pfizer
- Novartis
- Lantheus Medical Imaging
- Peloton Therapeutics, Inc.
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Eye Institute (NEI)
- Manhattan Eye, Ear & Throat Hospital
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
- Vanderbilt University
- University of Texas at Houston
- University of North Carolina at Chapel Hill
- LuEsther T. Mertz Retinal Research Center
Organization Involved with Phase 1 Indications (2)